Rigel Pharmaceuticals (RIGL) Cash from Operations Growth (3y) (2013 - 2026)
Rigel Pharmaceuticals (RIGL) Cash from Operations Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -5.07% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 33.08% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 16.64% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -7.60% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Rigel Pharmaceuticals | 681.25 Mn | 534.56 Mn | 54.21 Mn | 38.71% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 38.71% |
| Dec 31, 2025 | 44.28% |
| Sep 30, 2025 | 56.14% |
| Jun 30, 2025 | 63.43% |
| Mar 31, 2025 | 67.34% |
| Dec 31, 2024 | 40.27% |
| Sep 30, 2024 | 60.12% |
| Jun 30, 2024 | -82.38% |
| Mar 31, 2024 | 36.90% |
| Dec 31, 2023 | 26.28% |
| Sep 30, 2023 | 58.83% |
| Jun 30, 2023 | 34.30% |
| Mar 31, 2023 | -9.62% |
| Dec 31, 2022 | -31.44% |
| Sep 30, 2022 | 3.15% |
| Jun 30, 2022 | 8.13% |
| Mar 31, 2022 | -255.84% |
| Dec 31, 2021 | -53.82% |
| Sep 30, 2021 | 19.96% |
| Jun 30, 2021 | 59.34% |